Strong correlation between glycaemic variability and total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control

Diabetes and Metabolism

Volumn 40, Issue 4, 2014, Pages 272-277

  Suh, S ^a   Joung, J Y ^b   Jin, S M ^b   Kim, M Y ^b   Bae, J C ^b   Park, H D ^b   Lee, M S ^b   Lee, M K ^b   Kim, J H ^b  

^a Dong A University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

1,5 Anhydroglucitol; Continuous glucose monitoring systems; Fructosamine; Glycated albumin; HbA1c

Indexed keywords

1,5 ANHYDROSORBITOL; FRUCTOSAMINE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CARBOHYDRATE DIET; GLUCOSE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED SERUM ALBUMIN; SERUM ALBUMIN;

ADULT; ARTICLE; CONTINUOUS GLUCOSE MONITORING SYSTEM; FEMALE; GLYCEMIC CONTROL; GLYCEMIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MONITOR; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL GLUCOSE EXCURSION; POSTPRANDIAL STATE; TOTAL GLUCOSE EXPOSURE; ADMINISTRATION AND DOSAGE; AGED; BLOOD; CARBOHYDRATE DIET; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; FEMALE; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SERUM ALBUMIN;

EID: 84927175230     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2014.01.006     Document Type: Article

References (32)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus of Korean Diabetes Association Diabetes epidemics in Korea: reappraise nationwide survey of diabetes "diabetes in Korea 2007". Diabetes Metab J 2013, 37:233-239.
3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
4. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
5. Zheng F., Lu W., Jia C., Li H., Wang Z., Jia W. Relationships between glucose excursion and the activation of oxidative stress in patients with newly diagnosed type 2 diabetes or impaired glucose regulation. Endocrine 2010, 37:201-208.
6. Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999, 354:617-621. The DECODE study group, European Diabetes Epidemiology Group.
7. Frontoni S., Di Bartolo P., Avogaro A., Bosi E., Paolisso G., Ceriello A. Glucose variability: An emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract 2013.
8. American Diabetes A Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(SUPPL. 1):S11-S61.
9. Koga M., Saito H., Mukai M., Matsumoto S., Kasayama S. Influence of iron metabolism indices on glycated haemoglobin but not glycated albumin levels in premenopausal women. Acta Diabetol 2010, 47(SUPPL. 1):65-69.
10. Koga M., Hashimoto K., Murai J., Saito H., Mukai M., Ikegame K., et al. Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. Clin Chim Acta 2011, 412:253-257.
11. Koga M., Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010, 57:751-762.
12. Selvin E., Francis L.M., Ballantyne C.M., Hoogeveen R.C., Coresh J., Brancati F.L., et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 2011, 34:960-967.
13. Rodbard D. Clinical interpretation of indices of quality of glycemic control and glycemic variability. Postgrad Med 2011, 123:107-118.
14. DeVries J.H. Glucose variability: where it is important and how to measure it. Diabetes 2013, 62:1405-1408.
15. Kim S.K., Suh S., Kim M.Y., Chung H.S., Hur K.Y., Kim S.W., et al. Three-day continuous glucose monitoring for rapid assessment of hypoglycemic events and glycemic variability in type 1 diabetic patients. Endocr J 2011, 58:535-541.
16. Rohlfing C.L., Wiedmeyer H.M., Little R.R., England J.D., Tennill A., Goldstein D.E. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002, 25:275-278.
17. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009, 11(SUPPL. 1):S55-S67.
18. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., Taylor W.F. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970, 19:644-655.
19. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009, 11:551-565.
20. Molnar G.D., Taylor W.F., Ho M.M. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 1972, 8:342-348.
21. Yoshiuchi K., Matsuhisa M., Katakami N., Nakatani Y., Sakamoto K., Matsuoka T., et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J 2008, 55:503-507.
22. Iberg N., Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem 1986, 261:13542-13545.
23. Rondeau P., Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie 2011, 93:645-658.
24. Dungan K.M., Buse J.B., Largay J., Kelly M.M., Button E.A., Kato S., et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006, 29:1214-1219.
25. Kim M.J., Jung H.S., Hwang-Bo Y., Cho S.W., Jang H.C., Kim S.Y., et al. Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol 2013, 50:505-510.
26. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasmaglucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
27. Buse J.B., Freeman J.L., Edelman S.V., Jovanovic L., McGill J.B. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 2003, 5:355-363.
28. Yamanouchi T., Minoda S., Yabuuchi M., Akanuma Y., Akanuma H., Miyashita H., et al. Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 1989, 38:723-729.
29. Stettler C., Stahl M., Allemann S., Diem P., Schmidlin K., Zwahlen M., et al. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 2008, 31:1534-1535.
30. Koga M., Saito H., Mukai M., Otsuki M., Kasayama S. Serum glycated albumin levels are influenced by smoking status, independent of plasma glucose levels. Acta Diabetol 2009, 46:141-144.
31. Watanabe K., Uchino H., Ohmura C., Tanaka Y., Onuma T., Kawamori R. Different effects of two alpha-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level. J Diabetes Complications 2004, 18:183-186.
32. Koga M., Murai J., Saito H., Mukai M., Kasayama S. Serum glycated albumin, but not glycated haemoglobin, is low in relation to glycemia in hyperuricemic men. Acta Diabetol 2010, 47:173-177.